Literature DB >> 26363843

Long-term Outcomes of Patients with Acute Myocardial Infarction Presenting to Regional and Remote Hospitals.

Sradha Kotwal1, Isuru Ranasinghe2, David Brieger3, Philip Clayton4, Alan Cass5, Martin Gallagher3.   

Abstract

BACKGROUND: Acute myocardial infarction (AMI) has poorer outcomes in disadvantaged populations such as those in regional and remote locations. We compared long-term outcomes associated with presentation to regional or remote hospitals among AMI patients. METHODS AND
RESULTS: Administrative claims data from New South Wales (27% regional and remote residents) was used to identify patients >18 years admitted to any NSW hospital with a principal diagnosis of AMI (ICD10 codes: I21·0-I21·4) between 01/07/2004 and 30/06/2008. Hospital of presentation location with a population of <250,000 was defined as regional and remote while hospitals with a population >250,000 were deemed urban. Receipt of revascularisation and mortality were analysed and adjusted for age, comorbidities and previous revascularisation. Patients were censored at death or end of the follow-up period (31 December 2009). 39,798 patients were identified with 9,393 (23.6%) regional and remote presenters. In multivariable models, regional and remote presentation was associated with reduced rates of revascularisation (OR 0.30 95%CI 0.28-0.32; p<0.001), no impact on overall mortality (HR 1.04 95%CI 0.99-1.02; p=0.11), but with increased mortality for patients presenting with STEMI (HR 1.14; 95% CI 1.06-1.23; p<0.001). The propensity analysis was consistent with these findings.
CONCLUSIONS: Presentation to a regional and remote hospital was associated with lower revascularisation rates following AMI, but with a higher long-term mortality if presenting with ST segment elevation.
Copyright © 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; Mortality; Myocardial infarction; Revascularisation; Statistics

Mesh:

Year:  2015        PMID: 26363843     DOI: 10.1016/j.hlc.2015.07.019

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  4 in total

1.  Neutrophil-Derived S100A8/A9 Amplify Granulopoiesis After Myocardial Infarction.

Authors:  Gopalkrishna Sreejit; Ahmed Abdel-Latif; Baskaran Athmanathan; Andrew J Murphy; Prabhakara R Nagareddy; Rahul Annabathula; Ashish Dhyani; Sunil K Noothi; Gregory A Quaife-Ryan; Annas Al-Sharea; Gerard Pernes; Dragana Dragoljevic; Hind Lal; Kate Schroder; Beatriz Y Hanaoka; Chander Raman; Maria B Grant; James E Hudson; Susan S Smyth; Enzo R Porrello
Journal:  Circulation       Date:  2020-01-16       Impact factor: 29.690

Review 2.  Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox.

Authors:  Ingo Ahrens; Oleg Averkov; Eduardo C Zúñiga; Alan Y Y Fong; Khalid F Alhabib; Sigrun Halvorsen; Muhamad A B S K Abdul Kader; Ricardo Sanz-Ruiz; Robert Welsh; Hongbin Yan; Philip Aylward
Journal:  Clin Cardiol       Date:  2019-07-17       Impact factor: 2.882

3.  Acute myocardial infarction incidence and survival in Aboriginal and non-Aboriginal populations: an observational study in the Northern Territory of Australia, 1992-2014.

Authors:  Cushla Coffey; Yuejen Zhao; John R Condon; Shu Li; Steven Guthridge
Journal:  BMJ Open       Date:  2020-10-08       Impact factor: 2.692

4.  Rural and Remote Cardiology During the COVID-19 Pandemic: Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.

Authors:  Ruth H Arnold; Philip A Tideman; Gerard P Devlin; Gerard E Carroll; Alex Elder; Harry Lowe; Peter S Macdonald; Paul G Bannon; Craig Juergens; Mark McGuire; Justin A Mariani; Sean Coffey; Steven Faddy; Alex Brown; Sally Inglis; William Y S Wang
Journal:  Heart Lung Circ       Date:  2020-05-07       Impact factor: 2.975

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.